semaglutide select Trial: reduces the risk of MACE by 20% in people with overweight or obesity, pre-existing CVD, and no diabetes. Average weight loss of -9.4% at 51 months What the SELECT trial of

3 In the present case report even though the patient is giving a history of intake of thyroid medication, she failed to produce the physician's reports or the medications which she had taken for few months.On blood investigation her present T3,T4,TSH values are within normal limits.The lesion present in lower labial mucosa much more resembles like oral melanotic maculae

Chronic inflammation is a common complication of obesity and a known driver of cardiovascular and metabolic diseases

10.1038/s41598-024-54555-2 121 ZhaoG.LiX.ZhangY.WangX.DengL.XuJ.et al (2025a)

Cell Metab 2013

Some people may notice improvements within a few weeks, but for others, it might take a couple of months of consistent use to observe noticeable benefits

In addition, following the collapse of an aneurysm, its contents are released in the blood flow, inducing thrombosis